Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary

J Infect. 2021 Nov;83(5):559-564. doi: 10.1016/j.jinf.2021.08.031. Epub 2021 Aug 23.


Objectives: Scarce data are currently available on the kinetics of antibodies after vaccination with mRNA vaccines as a whole and, with mRNA-1273, in particular. We report here an ad-interim analysis of data obtained after a 6-month follow-up in a cohort of healthcare workers (HCWs) who received the mRNA-1273 vaccine. These new data provide more insight into whether and in whom a 3rd dose could be necessary.

Methods: Our study compared the anti-S antibody kinetics at 2 weeks (T1), 3 months (T3) and 6 months (T4) after the first injection, and 2 weeks after the second injection (T2). The 201 participating HCWs were stratified according to their initial serological status. The vaccine effectiveness was also assessed through a medical questionnaire.

Results: We report here a marked and statistically significant antibody decrease (P < 0.05) between T3 and T4, especially in naïve vaccinees. The analysis of potential confounding factors or known risk factors for severe COVID-19 disease did not reveal any influence on the drop observed. Six-month after vaccination, only one, symptomatic, infection was reported in our cohort.

Conclusions: In a supply-limited environment, our results plead for reserving the 3rd dose scheme, in the upcoming months, to seronegative individuals prior to vaccination, especially when the serological status is easily accessible.

Keywords: COVID-19; Efficacy; Immunogenicity; SARS-CoV-2; mRNA-1273 vaccine.

MeSH terms

  • 2019-nCoV Vaccine mRNA-1273
  • Antibodies, Viral
  • COVID-19 Vaccines*
  • COVID-19*
  • Health Personnel
  • Humans
  • Immunogenicity, Vaccine
  • RNA, Messenger
  • SARS-CoV-2


  • Antibodies, Viral
  • COVID-19 Vaccines
  • RNA, Messenger
  • 2019-nCoV Vaccine mRNA-1273